173 related articles for article (PubMed ID: 34182377)
1. The relationship between crystal methamphetamine use and methadone retention in a prospective cohort of people who use drugs.
Mackay L; Bach P; Milloy MJ; Cui Z; Kerr T; Hayashi K
Drug Alcohol Depend; 2021 Aug; 225():108844. PubMed ID: 34182377
[TBL] [Abstract][Full Text] [Related]
2. Methadone Maintenance Treatment Discontinuation Among Young People who use Opioids in Vancouver, Canada.
Pilarinos A; Kwa Y; Joe R; Dong H; Grant C; Fast D; Buxton JA; DeBeck K
Can J Psychiatry; 2023 Feb; 68(2):89-100. PubMed ID: 36377240
[TBL] [Abstract][Full Text] [Related]
3. Opioid agonist therapy engagement and crystal methamphetamine use: The impact of unregulated opioid use in Vancouver, Canada.
Cui Z; Bach P; Ti L; Hayashi K; Morgan J; Milloy MJ; Kerr T
Int J Drug Policy; 2022 Dec; 110():103879. PubMed ID: 36265327
[TBL] [Abstract][Full Text] [Related]
4. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
[TBL] [Abstract][Full Text] [Related]
5. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
6. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
[TBL] [Abstract][Full Text] [Related]
7. Crystal methamphetamine use and methadone maintenance treatment dissatisfaction: A prospective cohort study in Vancouver, Canada.
Cui Z; Hayashi K; Bach P; Milloy MJ; Kerr T
J Subst Use Addict Treat; 2023 Aug; 151():208956. PubMed ID: 36804867
[TBL] [Abstract][Full Text] [Related]
8. Predictors of crystal methamphetamine use initiation or re-initiation among people receiving opioid agonist therapy: A prospective cohort study.
Cui Z; Hayashi K; Bach P; Dong H; Milloy MJ; Kerr T
Drug Alcohol Depend; 2022 Nov; 240():109624. PubMed ID: 36116155
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with methadone maintenance therapy discontinuation among people who inject drugs.
Lo A; Kerr T; Hayashi K; Milloy MJ; Nosova E; Liu Y; Fairbairn N
J Subst Abuse Treat; 2018 Nov; 94():41-46. PubMed ID: 30243416
[TBL] [Abstract][Full Text] [Related]
10. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
[TBL] [Abstract][Full Text] [Related]
11. Increasing diversion of methadone in Vancouver, Canada, 2005-2015.
Reddon H; Ho J; DeBeck K; Milloy MJ; Liu Y; Dong H; Ahamad K; Wood E; Kerr T; Hayashi K
J Subst Abuse Treat; 2018 Feb; 85():10-16. PubMed ID: 29291766
[TBL] [Abstract][Full Text] [Related]
12. Impact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder in Canada.
Langlois J; Fairbairn N; Jutras-Aswad D; Le Foll B; Lim R; Socías ME
Am J Addict; 2024 Jun; ():. PubMed ID: 38877969
[TBL] [Abstract][Full Text] [Related]
13. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.
Socías ME; Wood E; Kerr T; Nolan S; Hayashi K; Nosova E; Montaner J; Milloy MJ
Drug Alcohol Depend; 2018 Aug; 189():90-95. PubMed ID: 29894910
[TBL] [Abstract][Full Text] [Related]
14. Methadone Dose, Cannabis Use, and Treatment Retention: Findings From a Community-based Sample of People Who Use Unregulated Drugs.
Lake S; Buxton J; Walsh Z; Cooper ZD; Socías ME; Fairbairn N; Hayashi K; Milloy MJ
J Addict Med; 2023 Jan-Feb 01; 17(1):e18-e26. PubMed ID: 35914028
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with discontinuation of methadone maintenance therapy (MMT) among persons who use alcohol in Vancouver, Canada.
Klimas J; Nosova E; Socías E; Nolan S; Brar R; Hayashi K; Milloy MJ; Kerr T; Wood E
Drug Alcohol Depend; 2018 May; 186():182-186. PubMed ID: 29604525
[TBL] [Abstract][Full Text] [Related]
16. The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting.
Mackay L; Kerr T; Fairbairn N; Grant C; Milloy MJ; Hayashi K
Addict Sci Clin Pract; 2021 Apr; 16(1):26. PubMed ID: 33910630
[TBL] [Abstract][Full Text] [Related]
17. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users.
Nolan S; Dias Lima V; Fairbairn N; Kerr T; Montaner J; Grebely J; Wood E
Addiction; 2014 Dec; 109(12):2053-9. PubMed ID: 25041346
[TBL] [Abstract][Full Text] [Related]
18. Correlates of methamphetamine use severity among patients receiving methadone maintenance treatment for opioid use disorder in Vietnam.
Giang LM; Li MJ; Okafor CN; Diep NB; Shoptaw SJ
J Subst Abuse Treat; 2022 Jan; 132():108461. PubMed ID: 34098204
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
[TBL] [Abstract][Full Text] [Related]
20. Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.
Moallef S; DeBeck K; Fairbairn N; Cui Z; Brar R; Wilson D; Johnson C; Milloy MJ; Hayashi K
Addict Sci Clin Pract; 2022 Dec; 17(1):73. PubMed ID: 36522789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
